

Anti-TNFRSF4/OX40/CD134 Antibody (Cudarolimab)

Introduction

Cudarolimab (IBI101) is a fully human anti-OX40 (CD134, a co-stimulatory molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has anti-tumor activity and can be used in cancer-related research.

Product parameters

Alternative Names	IBI-101, IBI101
Target Accession	P43489
Target	TNFRSF4 / OX40 / CD134
CAS number	2244739-29-3
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human TNFRSF4 His at 2 ug/mL can bind Anti-TNFRSF4/OX40/CD134 Antibody (Cudarolimab), EC50=0.009929 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

